HC Wainwright Weighs in on Indaptus Therapeutics, Inc.’s Q2 2024 Earnings (NASDAQ:INDP)

Indaptus Therapeutics, Inc. (NASDAQ:INDPFree Report) – Equities research analysts at HC Wainwright upped their Q2 2024 earnings per share (EPS) estimates for Indaptus Therapeutics in a note issued to investors on Monday, June 17th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings per share of ($0.54) for the quarter, up from their previous forecast of ($0.60). HC Wainwright has a “Buy” rating and a $12.00 price target on the stock. The consensus estimate for Indaptus Therapeutics’ current full-year earnings is ($1.72) per share. HC Wainwright also issued estimates for Indaptus Therapeutics’ Q4 2024 earnings at ($0.37) EPS, FY2024 earnings at ($1.72) EPS, Q1 2025 earnings at ($0.42) EPS, Q2 2025 earnings at ($0.38) EPS, Q3 2025 earnings at ($0.34) EPS and Q4 2025 earnings at ($0.33) EPS.

Indaptus Therapeutics (NASDAQ:INDPGet Free Report) last announced its quarterly earnings data on Wednesday, May 8th. The company reported ($0.45) EPS for the quarter, topping the consensus estimate of ($0.57) by $0.12.

Indaptus Therapeutics Stock Down 6.8 %

Shares of NASDAQ INDP opened at $2.32 on Wednesday. The firm has a market cap of $19.81 million, a PE ratio of -1.43 and a beta of 1.30. The company’s fifty day simple moving average is $2.39 and its 200 day simple moving average is $2.10. Indaptus Therapeutics has a 12-month low of $1.56 and a 12-month high of $4.08.

Hedge Funds Weigh In On Indaptus Therapeutics

An institutional investor recently bought a new position in Indaptus Therapeutics stock. Virtu Financial LLC acquired a new stake in Indaptus Therapeutics, Inc. (NASDAQ:INDPFree Report) during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm acquired 14,232 shares of the company’s stock, valued at approximately $32,000. Virtu Financial LLC owned approximately 0.17% of Indaptus Therapeutics at the end of the most recent quarter. Institutional investors and hedge funds own 7.06% of the company’s stock.

About Indaptus Therapeutics

(Get Free Report)

Indaptus Therapeutics, Inc, a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial.

Recommended Stories

Earnings History and Estimates for Indaptus Therapeutics (NASDAQ:INDP)

Receive News & Ratings for Indaptus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indaptus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.